0.255
0.00 (0.00%)
| Previous Close | 0.255 |
| Open | 0.250 |
| Volume | 2,467,998 |
| Avg. Volume (3M) | 3,293,301 |
| Market Cap | 371,175,456 |
| Price / Sales | 1.32 |
| Price / Book | 2.15 |
| 52 Weeks Range | |
| Earnings Date | 29 Jul 2025 - 4 Aug 2025 |
| Operating Margin (TTM) | -839.24% |
| Diluted EPS (TTM) | -0.030 |
| Quarterly Revenue Growth (YOY) | 49.10% |
| Total Debt/Equity (MRQ) | 0.98% |
| Current Ratio (MRQ) | 18.86 |
| Operating Cash Flow (TTM) | -44.92 M |
| Levered Free Cash Flow (TTM) | -31.56 M |
| Return on Assets (TTM) | -20.35% |
| Return on Equity (TTM) | -30.45% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (AU) | Mixed | Mixed |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | IMMUTEP FPO [IMM] | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 4.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -2.5 |
| Average | -0.13 |
|
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 3.32% |
| % Held by Institutions | 42.65% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |